Understanding Hodgkin’s Lymphoma: The Role of Tumour Cells and Immune Microenvironment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: 29 November 2024 | Viewed by 1660
Special Issue Editor
Interests: pathology; surgical pathology; oncologic pathology; molecular pathology; dermatopathology; hematopathology; head and neck pathology; endocrine pathology; nodal and extranodal lymphoma
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The dynamic interaction of neoplastic cells with the surrounding microenvironment, comprised of stromal cells and an extracellular matrix, is essential. This process promises to support the heterogeneity of the tumour compartment, and to assist in overcoming inadequate responses to therapy and increased multidrug resistance.
In this context, Hodgkin's lymphoma (HL), one of the most enigmatic cancers in which few neoplastic cells are within an abundant but ineffective immune ecosystem, represents a paradigmatic tumour for study.
The pathways associated with the development and homeostasis of tissues, such as NF-κB, Notch, JAK / STAT, and, as increasingly demonstrated by more advanced studies, the tumour microenvironment, are involved in the pathogenesis of this disease.
B and T non-neoplastic lymphocytes, with their subpopulations, plasma cells, macrophages, myeloid-derived suppressor cells, mast cells and natural killer cells are, albeit in different ways, essential for the growth and survival of Sternberg / Hodgkin (RS/H cells).
HRS cells functionally reprogram non-neoplastic elements via the cross-talk complex to receive survival stimuli and escape immune surveillance. However, the underlying links between the tumour and the microenvironment are not fully established and require further investigation.
For this Special Issue, we welcome articles or reviews on discoveries or new concepts to clarify the interaction between cancer, non-neoplastic cells and stroma, emphasise how this could be targeted to reduce tumour progression and loss of response to therapy, and highlight the prospects for improvement in patient management.
I look forward to receiving your contributions.
Prof. Dr. Massimo Mascolo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
